Proterris, Inc. Information

Carbon monoxide (“CO”) has long been recognized and studied for its therapeutic potential given its unique and potent cytoprotective, anti-inflammatory and anti-fibrotic effects. Importantly, CO’s therapeutic effects are achieved at doses far less than what is already firmly established in the literature and clinical practice as toxic levels. To harness this broad potential, Proterris has amassed a broad array of inhaled & small molecule CO therapeutics for transplant, nephrology, pulmonary and oncology indications, which together address a treatable patient population of more than 20 million patients in the U.S. alone. Our current focus is on a) a Phase 2b/3 study of DGF prevention in kidney transplant recipients, for which we have approval from the UK MHRA and are in the process of expanding the trial into the U.S. and EU and b) a Phase 2a study in PGD prevention in lung transplant recipients, for which we are filing an IND with the US FDA in 1H2026.